The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms SELECT
  • Most Recent Events

    • 18 May 2017 Status changed from active, no longer to completed.
    • 18 May 2017 Status changed from active, no longer to completed.
    • 05 Mar 2010 Results presented at ASCO Genitourinary Cancers Symposium 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top